Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Clinical Study of the Safety and Pharmacokinetics of Alofanib in Patients With Metastatic Gastric Cancer Resistant to Standard Therapy

NCT04071184 is registered in ClinicalTrials.gov with Russian Pharmaceutical Technologies as lead sponsor.

NCT NCT04071184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04071184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Clinical Study of the Safety and Pharmacokinetics of Alofanib in Patients With Metastatic Gastric Cancer Resistant to Standard Therapy
Lead sponsor
Russian Pharmaceutical Technologies
Phase
Phase 1
Overall status
Unknown status
Start date
May 26, 2019
Completion date
December 1, 2020
Enrollment
50 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer